Moreover, the therapeutic efficacy of mSWI/SNF ATPase degraders in SCLC-P suggests broader implications whereby other POU2F3-expressing small cell carcinomas may respond to this targeted therapy. The gene discussed is POU2F3; the disease is small cell lung carcinoma.